Background
==========

Several studies have reported that some medicinal herbs alter diuresis \[[@B1]-[@B5]\] even though little is known about the mechanism(s) that account for this claimed physiological effect. *Ampelozizyphus amazonicus* (*A. amazonicus*) is a Rhamnaceae known as 'saracura-mirá' or 'Indian beer' that is traditionally used by Brazilian Indians and Cabocos (from the Tupi *kaa\'boc*) who live in all regions along Rio Negro, Amazônia. Beverages prepared with their roots are used as stimulant against tiredness, fatigue and starvation \[[@B6]\]). The beverage is also used against malaria, liver disturbances and sleeplessness, and serve as depurative \[[@B7]\].

In a previous studies, we have shown that a triterpene saponin mixture isolated from the roots of *A. amazonicus* Ducke (SAP*Aa*D), reduced the urine excretion of normal rats in a dose-dependent manner \[[@B8]\]. There is a need for novel oral antidiuretics to treat diseases, such as pituitary diabetes insipidus and nephrogenic diabetes insipidus; however, investigations for compounds other than the typically used arginine vasopressin (AVP) or desmopressin are lacking. It is well known that diuresis is regulated by a number of endogenous and exogenous compounds that act at multiple intrarenal sites to influence urine formation \[[@B9]\]. The final urine volume and composition are determined primarily in the renal tubule system without a direct extensive dependence on the glomerular filtration rate. In the renal tubules, water reabsorption is usually secondary to transcellular sodium reabsorption. Additionally, AVP regulates water balance and osmolality by manipulating water permeability that is not obscured by responses to sodium reabsorption \[[@B10]\]. Renal tubular sodium reabsorption involves two primary active transporters: the ouabain-sensitive (Na^+^,K^+^)-ATPase and the furosemide-sensitive Na^+^-ATPase \[[@B9]-[@B11]\]. The activity of both ATPases is directly regulated by hormones, such as natriuretic peptides. These hormones play an important role in hydroelectrolytic homeostasis by stimulating natriuresis through the coordination of apical sodium channels and basolateral (Na^+^,K^+^)-ATPases in the inner medullary collecting ducts \[[@B12]-[@B16]\]. Over the last few decades, several studies have demonstrated the potential role of the cortical sodium pumps in the composition of excreted urine. The various hormones that play a role in the modulation of urine composition act on these sodium pumps in the cortical segment, particularly in the proximal tubule \[[@B17]-[@B19]\]. Accordingly, it is well known that specific modifications of sodium reabsorption in the proximal tubule cells lead to an increase in renal sodium and water excretion as observed in primary hypertension \[[@B20]-[@B23]\]. Then, it is plausible to postulate that changes in the cortical sodium pumps promoted by a compound could lead to changes in urine composition. It has been reported that sodium pumps' activities can be modulated by herbal products, such as *Petroselinum hortense* extracts*,* which inhibit (Na^+^,K^+^)-ATPase, and saponins isolated from *Costus spicatus* Swartz, which inhibit Na^+^-ATPase activity \[[@B24],[@B25]\]. Because the inhibition of renal Na^+^ transport may account for the diuretic effect of different agents, we investigated the renal cortical Na^+^ pumps and renal natriuretic peptides in SAP*Aa*D-induced antidiuresis.

Methods
=======

Plant material
--------------

The roots of *A. amazonicus* Ducke were collected (September, 2000) in the city of Presidente Figueiredo, Amazonas State, Brazil, and were identified by Dr. Ari Hidalgo. Voucher specimens (189,858) were deposited in the herbarium of the Instituto Nacional de Pesquisa da Amazônia (Manaus/AM, Brazil).

Extraction, isolation and characterization of SAP*Aa*D
------------------------------------------------------

The extraction, isolation and chemical characterization of SAP*Aa*D were performed according to previously described procedures \[[@B8]\]. Powdered roots of *A. amazonicus* were successively extracted by percolation with 70 % ethanol, with the solvent then evaporated to dryness (6.6 % w/w). The crude extract was resuspended in water and treated with n-butanol. After evaporation at a maximum of 60°C, the organic and aqueous phases furnished the SAP*Aa*D and saponin-free (SAP*Aa*D-free) fractions, respectively. Chemical characterisation was performed by HPLC/DAD. Briefly, HPLC analysis was carried out on an Agilent 1200 system (Palo Alto, CA, USA). Column, lichrospher reversed-phase C~18~ (250 mm x 4.6 mm I.D., 5 μm particle size, Merck); mobile phase, acetonitrile (solvent A) and water (solvent B); elution gradient, 30--40 % A at 0--10 min, 40--90 % A at 10--40 min, 90--100 % A at 40--45 min, and 100 % A at 45--50 min; flow rate, 1.0 mL/min; injection volume, 20 μL. For the analysis, 30 mg of SAP*Aa*D were dissolved in 10 mL of acetonitrile:water (30:70) in an ultrasonic bath for 10 min. All solutions were filtered through a 0.45 μm membrane filter before injection. UV photodiode array detection was performed at 205 nm, and UV spectra from 200 to 400 nm were on-line recorded for peak identification.

Animals
-------

Male Wistar rats weighing 250--300 g were housed in standard conditions with free access to commercial chow and water prior to the experiment. Animals were kept at a room temperature of 22°C with a light/dark cycle of 14/10 h. All procedures described here had prior approval from the Institutional Animal Use Ethics Committee (protocol 177, November, 2008).

Interaction between furosemide and SAP*Aa*D
-------------------------------------------

To evaluate a possible interaction between furosemide (Lasix®, Aventis Pharma Ltda, São Paulo, Brazil) and SAP*AaD*, all animals were given an oral loading of physiological solution (0.9 % NaCl, 4 ml/100 g body weight) to impose a uniform water and salt state. The physiological solution containing furosemide (13 mg/kg) was given 30 min after rats were orally treated with 50 mg/kg SAP*Aa*D (*SAPAaD + Furo* group) or 0.5 ml of 0.9 % NaCl (*NaCl + Furo* group). Rats of group *SAPAaD + NaCl* were pretreated with SAP*Aa*D and 30 min later they received the oral loading of physiological solution. Rats in the *NaCl + AVP* group received the physiological solution containing 200 ng/kg AVP (Sigma Chemical Co., St Louis, MO, USA, 98 % purity) after (30 min) rats were orally treated with 0.5 ml of 0.9 % NaCl. Rats in the *NaCl + NaCl* group received the oral loading of physiological solution after pretreatment with 0.5 ml of 0.9 % NaCl (control). Animals were individually housed in metabolic cages, and urine volume was measured every 30 min throughout the experiment (3 h).

In a series of experiments, rats were given the oral loading of physiological solution as above in the absence (control) and presence of 50 mg/kg SAP*Aa*D. At 90 min after SAP*Aa*D administration, the urine volume was measured, and a sample of urine was collected and stored at −20°C until the measurement of urine ANP was performed. Afterward, the rats were anesthetized with 40 mg/kg of thiopental, and a blood sample was drawn from the inferior cava vein. Under anesthesia, the rats were sacrificed, and the kidneys were removed for the histomorphological analysis and the renal ATPase activity measurements. Both atria were also removed to determine the ANP content. Blood samples were centrifuged at 3,000 rpm for 10 min at 4°C, and the recovered plasma was stored at −80°C until the ANP assay was performed. For the histomorphological analysis, sections of the kidney were obtained from representative animals in the control and SAP*Aa*D-treated groups. The tissue was fixed in 10 % formalin, embedded in paraffin and was dissected into 4 μm sections. The sections were stained with hematoxylin and eosin and were examined under a light microscope.

Measurement of renal ATPases' activities
----------------------------------------

The kidneys were removed immediately after the rats were sacrificed under anesthesia and were maintained in a cold isosmotic solution containing 250 mM sucrose, 10 mM HEPES-Tris, pH 7.6, 2 mM ethylenediaminetetraacetic acid (EDTA) and 1 mM phenylmethylsulfonyl fluoride (PMSF). Thin slices of cortex (cortex-corticis) were separated using a scalpel and homogenized in the same cold solution with a teflon and glass homogenizer. The homogenate was centrifuged for 10 min at 10,000 rpm in a Sorvall centrifuge using an SS-34 rotor at 4°C. The pellet was discarded and the supernatant was centrifuged for 1 h at 60,000 rpm at 4°C. The membrane pellet containing the microsomal fraction was resuspended in 250 mM sucrose to a final concentration of 6--10 mg of protein per milliliter and was stored at 4°C. ATPase activity was measured as previously reported \[[@B26]-[@B28]\]. Na^+^-ATPase and (Na^+^,K^+^)-ATPase activities expressed in nmol Pi x mg^-1^ x min^-1^ were obtained by subtracting the enzyme activity in the absence and presence of furosemide (2 mM) and ouabain (1 mM), respectively \[[@B27],[@B28]\].

Measurement of atrial natriuretic peptides
------------------------------------------

To determine the atrial content of ANP, the left and right atria were pooled in a prechilled tube containing a cocktail of protease inhibitors consisting of 0.1 M acetic acid, 10^-5^ mol/L EDTA, 10^-5^ mol/L PMSF and 0.5 x 10^-5^ mol/L pepstatin A (Sigma Chemical Co., St. Louis, MO, USA). The tube contents were homogenized (Euroturrax homogenizer T20b; Janke and Kunkel Ika Labortechnik, Staufen, Germany) and centrifuged at 20,000 x g for 30 min at 4°C. The supernatants were diluted in a phosphosaline buffer (0.01 mol/L sodium phosphate, 0.14 mmol/L bovine serum albumin, 0.10 % Triton X-100, 0.10 mol/L NaCl and 0.01 % sodium azide, pH 7.4), and ANP content was determined by radioimmunoassay (RIA) \[[@B29]\]. ANP antibody was kindly donated by Dr. J Gutkowska (CHUM -- Université de Montreal, Montreal, Canada). Standard ANP was obtained from Bachem Inc. (Torrance, CA, USA). The protein concentration in the supernatant was measured as previously described \[[@B30]\]. Atrial ANP was normalized to protein concentration and reported in micrograms per milligram of protein. To quantify plasma ANP, plasma samples (1 mL) were extracted in Sep-Pak C~18~ cartridges (Waters Corporation, Milford, MA, USA). Eluents were evaporated until dry in a Speed-Vac (Eppendorf 5301, Hamburg, Germany), and the resultant powder was dissolved in 500 μL of phosphosaline buffer prior to determining the ANP concentration by RIA \[[@B29]\]. To quantify the urine ANP, 1 mL of urine was extracted using Sep-Pak C~18~ cartridges (Waters Corporation, Milford, MA, USA), as previously described \[[@B29]\]. After being evaporated until dry in a Speed-Vac, the samples were dissolved in 500 μL of phosphosaline buffer, and urine ANP was determined by RIA using anti-ANP antibodies. Because atrial ANP and urine ANP have a very similar structure with an identical C-terminus \[[@B31]\], anti-ANP antibodies may also be employed to measure ANP in urine. In addition, insignificant concentrations of circulating ANP are found in the urine because of high ANP degradation from peptidases in the kidney cortex membranes or because of ANP binding to the clearance C receptor \[[@B32],[@B33]\].

Statistical analysis
--------------------

The results were expressed as means ± standard error of the mean (± SEM). The data shown the effect of SAPAaD and furosemide on diuresis were analyzed using nonlinear regression and two-way ANOVA followed by Bonferroni's test. To analyze the other investigated parameters, unpaired Student's *t*-test was also employed to compare the control and SAP*Aa*D-treated groups. A p-value less than 0.05 (p \< 0.05) was considered statistically significant.

![**HPLC fingerprinting of SAP*Aa*D.** The retention times of saponins are (in min): **1**--9.42, **2**--9.85, **3**--11.32, **4**--13.46, **5**--13.79, **6**--14.75 and 7--16.78. Detection, 205 nm; mAU, milli absorbance unit.](1472-6882-12-40-1){#F1}

Results
=======

Figure [1](#F1){ref-type="fig"} shows a typical fingerprint chromatogram of SAP*Aa*D mixture. The retention times of saponins were between 9.42 and 16.78 min. The purification process performed to obtain saponins was very efficient since the peaks related to saponins were predominant in the SAP*Aa*D fraction fingerprint.

![**Effect of SAP*Aa*D and furosemide on diuresis in rats.** Animals were given an oral loading of physiological solution (0.9 % NaCl, 4 ml/100 g body weight) to impose a uniform water and salt state. In **A**: Rats were orally pretreated (30 min) with 0.5 ml 0.9 % NaCl and received the physiological solution alone (*NaCl + NaCl*) or containing 13 mg/kg furosemide (*NaCl + Furo*); *SAPAaD + NaCl,* rats were orally pretreated with 50 mg/kg SAP*Aa*D and received the physiological solution alone. In **B**: Rats were orally pretreated with SAP*Aa*D and received the physiological solution containing furosemide (*SAPAaD + Furo*); *NaCl + AVP*, rats were orally pretreated with 0.5 ml 0.9 % NaCl and received the physiological solution containing AVP. *NaCl + Furo* is the same as in **A**. Animals (n = 5/group) were individually housed in metabolic cages, and urine volume was measured every 30 min throughout the experiment (3 h). Data are expressed as means ± SEM. In **A**, \**p* \< 0.05 vs. group *NaCl + NaCl*. In **B**,\**p* \<0.05, \*\**p* \< 0.01 and \*\*\**p* \< 0.001 vs. group *NaCl + Furo* at the correspondent time. Data were analyzed by two-way ANOVA followed by Bonferroni's test.](1472-6882-12-40-2){#F2}

All experiments using animals were performed in rats with a 4 % body weight volume expansion (oral loading of 0.9 % NaCl, 4 ml/100 g body weight) because this magnitude of volume expansion is an intermediate value between the experimentally obtainable minimum and maximum values used for studies examining the acute effect of substances that either stimulate or inhibit diuresis. In this study, SAP*Aa*D was tested at the dose of 50 mg/kg because it resulted in an approximate 60 % reduction in the diuresis induced by the oral loading of 0.9 % NaCl (4 ml/100 g body weight) in normal rats. This reduction was reported in our previous study \[[@B8]\] in which we have shown that SAP*Aa*D at dose varying from 25 to 1000 mg/kg reduced the urine production in a dose-dependent manner. As 60 % reduction neither represent the minimum nor the maximum effect of SAP*Aa*D, 50 mg/kg was the dose of choice to perform the experiments in the present study. No significant alteration of renal morphology was observed after SAP*Aa*D treatment (data not shown).

Interaction between furosemide and SAP*Aa*D
-------------------------------------------

As shown in Figure [2](#F2){ref-type="fig"}, SAP*Aa*D and furosemide have antagonistic effects on diuresis. While SAP*Aa*D reduced the diuresis elicited by the oral loading of 0.9 % NaCl (at 180 min: from 8.5 ± 1.0 mL, *NaCl + NaCl* group, to 4.0 ± 1.3 mL, *SAPAaD + NaCl* group, n = 5) (Figure [2A](#F2){ref-type="fig"}), furosemide dosed at 13 mg/kg greatly increased urine elimination in rats that equally received oral 0.9 % NaCl (at 180 min: from 8.5 ± 1.0 mL to 12.2 ± 1.4 mL, *NaCl + Furo* group, n = 5) (Figure [2A](#F2){ref-type="fig"}). However, pretreatment with SAP*Aa*D eliminates this increase in the furosemide-induced diuresis (Figure [2B](#F2){ref-type="fig"}). In the presence of SAP*Aa*D, the urine volume produced by furosemide (8.5 ± 1.3 mL, *SAPAaD + Furo* group n = 5) (Figure [2B](#F2){ref-type="fig"}) was similar to that observed in the *NaCl + NaCl* group (8.5 ± 1.0 mL, n = 5) (Figure [2A](#F2){ref-type="fig"}) at 180 min. It is noteworthy that SAP*Aa*D, although in a less extent, induced antidiuresis as AVP, which was used as a positive control (Figure [2B](#F2){ref-type="fig"}).

Effect of SAP*Aa*D on renal ATPases' activities and atrial natriuretic peptides
-------------------------------------------------------------------------------

SAP*Aa*D (50 mg/kg) significantly increased the activities of renal Na^+^-ATPase (from 25.0 ± 5.9 nmol Pi. mg^-1^. min^-1^, control, n = 4, to 52.7 ± 8.9 nmol Pi.mg^-1^. min^-1^, n = 4, p \< 0.05) (Figure [3A](#F3){ref-type="fig"}) and renal (Na^+^, K^+^)-ATPase (from 47.8 ± 13.3 nmol Pi.mg^-1^.min^-1^, control, n = 4, to 79.8 ± 6.9 nmol Pi.mg^-1^.min^-1^, n = 4, p \< 0.05) (Figure [3B](#F3){ref-type="fig"}). The ANP levels in both the plasma (Figure [4A](#F4){ref-type="fig"}, n = 6) and atria (Figure [4B](#F4){ref-type="fig"}, n = 6) were not significantly affected by SAP*Aa*D at the 50 mg/kg dosage. In contrast, urine ANP excretion was significantly reduced in the rats treated with SAP*Aa*D (from 792 ± 132 pg/mL, control, n = 7, to 299 ± 88 pg/mL, n = 7, p \< 0.01) (Figue [4C](#F4){ref-type="fig"}).

![**Effect of SAP*Aa*D on renal Na**^**+**^**- (A) and (Na**^**+**^**, K**^**+**^**)-ATPase activities (B).** Rats were given an oral loading of physiological solution (0.9 % NaCl, 4 ml/100 g body weight) in the absence (control) and presence of 50 mg/kg of SAP*Aa*D). At 90 min after SAP*Aa*D administration, rats were sacrificed, and the kidneys were removed for renal cortical ATPase measurement. ATPases' activities were expressed as nmol Pi per milligram of total protein per minute. Data are expressed as means ± SEM of four rats/group. \**p* \< 0.05 compared with the control group, unpaired Student's *t*-test.](1472-6882-12-40-3){#F3}

![**Effects of SAP*Aa*D on plasma (A), atria (B) and urine (C) ANP.** Rats received an oral loading of physiological solution (0.9 % NaCl, 4 ml/100 g body weight) in the absence (control) and presence of 50 mg/kg of SAP*Aa*D). At 90 min after SAP*Aa*D administration, a sample of blood and urine were collected, rats were sacrificed and the atria were removed for ANP measurement. Plasma (n = 6), pooled left and right atria (n = 6) and urine ANP (n = 7) were measured by RIA. Atria ANP were normalized to protein concentration and reported in micrograms per milligram of protein. Data are represented as means ± SEM. ANP in control: Plasma and atria (n = 12) and urine (n = 7). \*\**p* \< 0.01 compared with the control group, unpaired Student's *t*-test.](1472-6882-12-40-4){#F4}

Discussion
==========

In this study, we showed for the first time that saponins, in vivo, stimulate renal ATPases and reduce the level of urine ANP. These effects are undoubtedly characteristic of an antidiuretic agent. Moreover, SAP*Aa*D abolished the diuretic effect of furosemide, a classical diuretic that affects renal Na^+^-ATPases \[[@B32]\]. In a previous study, our group reported that the oral administration of SAP*Aa*D exhibited a dose-dependent antidiuretic effect in normal rats in either dehydrated or hydrated conditions \[[@B8]\]. In the present study, SAP*Aa*D exhibited a similar effect even when administered 30 min prior to an oral loading of physiological solution (0.9 % NaCl). Because pretreatment with SAP*Aa*D prevented the effect of furosemide, one could expect that SAP*Aa*D might share the same mechanistic pathway by which furosemide enhances diuresis. According to Becker et al. \[[@B34]\], the diuretic effect of furosemide was reduced in hypertensive patients with domiciliary use of a nutritional supplement derived from ginseng. Ginseng is a natural compound that is rich in triterpene saponins structurally similar to SAP*Aa*D. It is known that furosemide inhibits renal Na^+^-ATPase activity \[[@B11],[@B32]\]. In addition, some studies have reported that the activities of renal ATPases may be modulated by medicinal plants. It has been shown that the diuretic effect of crude *Petroselinum hortense* extract is accompanied by the inhibition of (Na^+^,K^+^)-ATPase activity \[[@B25]\]. Na^+^-ATPase was similarly inhibited by steroidal saponins isolated from *Costus spicatus*, a plant used in Brazilian folk medicine to expel kidney stones \[[@B24]\]. In contrast, the present study shows SAP*Aa*D in vivo produced a significant increase in both Na^+^- and (Na^+^,K^+^)-ATPase activities. These data suggest that SAP*Aa*D decreased the diuresis, at least in part, by stimulating renal ATPases. Accordingly, it was previously reported that saponins unmask a latent intracellular pool of (Na^+^,K^+^)-ATPase leading to an increase in the renal tubular ATPase activity \[[@B35],[@B36]\]. It has been reported that endogenous compounds, such as ANP~99-126~ and urodilatin \[[@B12]-[@B14]\], stimulate natriuresis and diuresis primarily by coordinating the inhibition of apical Na^+^ channels and basolateral (Na^+^,K^+^)-ATPases in the inner medullary collecting ducts \[[@B12]\]. However, a possible role of the cortical sodium pumps in the urine final composition cannot be ruled out. Different hormones that modulate the urine composition act on these cortical sodium pumps located particularly in the proximal tubules \[[@B17]-[@B19]\]. It is well established that specific modifications in sodium reabsorption in proximal tubule cells lead to an increase in renal sodium and water excretion as observed in primary hypertension \[[@B20]-[@B23]\]. These observations indicate that changes in the cortical sodium pumps may lead to changes in urine composition. In addition, alteration in the renal and/or plasma levels of the natriuretic peptides may play a role in the SAP*Aa*D-induced antidiuresis. A significant reduction in the urine ANP concentration was observed in the urine of rats treated with SAP*Aa*D. Therefore, we cannot exclude the possibility that the increase in renal ATPase activity induced by SAP*Aa*D was a result of the reduction in the renal urodilatin level. This explanation is, at least in part, consistent with the observation that renal urodilatin inhibits Na^+^-ATPase activity but not (Na^+^,K^+^)-ATPase activity in proximal tubules \[[@B37]\]. However, in a previous study \[[@B38]\], it was shown that exogenous urodilatin dosed at 10 nM increased the (Na^+^,K^+^)-ATPase activity in the renal outer cortex of Sprague--Dawley rats. The discrepancy between this study and our investigation may be because (Na^+^,K^+^)-ATPase activity was measured in the whole cortex and because the urine ANP excretion was lower than the exogenous urodilatin used in the previous study (10 nM). Natriuretic peptides are very important hormones that regulate renal processes since they are effective at promoting changes in renal vasculature by acting as vasodilators, and renal tubules by reducing Na^+^ and water reabsorption. In our study, the reduction in the urine ANP may denote a decreased intrarenal ANP content. In turn, the low level of renal ANP would not modulate the activity of renal cortical Na^+^ pumps resulting in a higher Na^+^ reabsorption. As a consequence, the urinary elimination of salts and water is diminished.

Conclusions
===========

Although the precise mechanism by which SAP*Aa*D affect diuresis is not completely elucidated, our data indicate that the antidiuretic effect of SAP*Aa*D may be due to a reduction in the renal ANP levels and/or an increase in the renal ATPase activity. We also conclude that saponins from *A. amazonicus* Ducke might be an herbal candidate for an antidiuretic with therapeutic potential. On the other hand, the *A. amazonicus* Ducke species should be used with caution because antidiuretic agents should be avoided in certain conditions, such as hypertension.
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